OCD Releases Anti-HIV Test
Ortho Clinical Diagnostics, Raritan, NJ, announced today FDA approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS 5600 Integrated and VITROS 3600 Immunodiagnostic Systems.
This is the first HIV diagnostic assay approved for an integrated system in the United States, allowing laboratories to run HIV and other routine tests on a single testing platform and eliminating the need for expensive batch testing of multiple patient samples, according to a company press release.
“By providing a fast, cost-effective and reliable method for testing HIV, the VITROS Anti-HIV 1+2 Assay will help enhance the clinical laboratory’s ability to adhere to the CDC HIV screening guidelines, while at the same time increasing the lab’s productivity and efficiency,” said Mike Samoszuk, MD, chief medical officer, Ortho Clinical Diagnostics. “This approval underscores Ortho Clinical Diagnostics’ continuing commitment to providing clinical laboratories with tests that help detect diseases earlier for better patient outcomes.”